Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.

500 Background: Bv improves progression-free survival (PFS) but not overall survival (OS) in MBC. E5103 added Bv to adjuvant therapy in patients (pts) with HER2- disease. Methods: Pts were assigned...